Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,026 | 165 | 831 |
| Samples | 349 | 78 | 265 |
| Peptides | 295 | 59 | 228 |
Function
PHC1 · Polyhomeotic homolog 1
This gene is a homolog of the Drosophila polyhomeotic gene, which is a member of the Polycomb group of genes. The gene product is a component of a multimeric protein complex that contains EDR2 and the vertebrate Polycomb protein BMH1. The gene product, the EDR2 protein, and the Drosophila polyhomeotic protein share 2 highly conserved domains, named homology domains I and II. These domains are involved in protein-protein interactions and may mediate heterodimerization of the protein encoded by this gene and the EDR2 protein. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 278 amino-acid changes on canonical ENST00000544916 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in PHC1 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in PHC1 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 4/40 10% | 0/0 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 6/133 5% |
| Endometrial Carcinoma | 2/42 5% | 15/612 2% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Squamous Cell Lung Carcinoma | 6/57 11% | 8/810 1% |
| Colorectal Carcinoma | 12/143 8% | 41/3239 1% |
| Gastric Carcinoma | 3/74 4% | 25/1809 1% |
| Rhabdomyosarcoma | 2/33 6% | 1/171 1% |
| Osteosarcoma | 3/45 7% | 0/166 0% |
| Ovarian Carcinoma | 6/109 6% | 9/998 1% |
| Other Solid Cancers | 1/94 1% | 20/1515 1% |
| Non-Small Cell Lung Carcinoma | 11/304 4% | 10/1390 1% |
| Melanoma | 4/210 2% | 21/1899 1% |
| Neuroendocrine Tumour | 6/154 4% | 2/577 0% |
| Bladder Carcinoma | 0/58 0% | 10/956 1% |
| Ewings Sarcoma | 1/63 2% | 2/262 1% |
| Cervical Carcinoma | 2/35 6% | 2/422 0% |
| Hepatocellular Carcinoma | 1/46 2% | 16/2210 1% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 5/752 1% |
| Thyroid Gland Carcinoma | 1/45 2% | 8/1592 0% |
| Non-Cancerous | 0/104 0% | 5/830 1% |
| Glioma | 0/52 0% | 10/2127 0% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 10/2550 0% |
| Medulloblastoma | 0/0 0% | 2/450 0% |
| Biliary Tract Carcinoma | 0/54 0% | 4/950 0% |
| Meningioma | 1/3 33% | 0/252 0% |
| Breast Carcinoma | 2/144 1% | 9/3264 0% |
| Kidney Carcinoma | 1/85 1% | 5/1862 0% |
| Head and Neck Carcinoma | 0/85 0% | 5/1574 0% |
Mutation Distribution
Where PHC1 is mutated · all tissues, split by cell line vs tissue
How many mutations in PHC1 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,026 mutations in PHC1
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|